AMS Settles With Celsion Over Prostate Product
Under the terms of the settlement, which was announced Thursday, Celsion will pay AMS a licensing fee and ongoing royalty payments. In return, AMS will drop the suit, and Celsion will continue selling its Prolieve product in the United States.
The financial terms of the deal remain undisclosed.
“Intellectual property fuels the engine of [our] pelvic health innovation,” said Ross Longhini,...
To view the full article, register now.